Literature DB >> 31612498

miR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells.

Jie Li1, Songlin Zhang2, Yuliang Zou3, Lei Wu3, Meili Pei3, Yu Jiang3.   

Abstract

Ovarian cancer presents as malignant tumors in the female reproductive system with high mortality. MicroRNAs are involved in the progression of ovarian cancer; however, the regulatory relationship among miRs remains unclear. In our study, we verified that both miR-145 and miR-133b messenger RNA (mRNA) levels in ovarian cancer tissues were lower than in normal ovarian tissues, and their mRNA level in serum of patients with ovarian cancer was reduced. We demonstrated miR-145 targeted c-myc, and c-myc interacted physically with DNMT3A in ovarian cancer cells. We confirmed that c-myc recruited DNMT3A to the miR-133b promoter. miR-133b overexpression also inhibited target gene PKM2 expression along with the Warburg effect. Our results indicate that miR-145 inhibited the Warburg effect through miR-133b/PKM2 pathways, which may improve approaches to ovarian cancer diagnosis and treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  DNMT3A; Warburg effect; c-myc; miR-133b; miR-145; ovarian cancer

Mesh:

Substances:

Year:  2019        PMID: 31612498     DOI: 10.1002/jcp.29306

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  15 in total

Review 1.  The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.

Authors:  Dexter L Puckett; Mohammed Alquraishi; Winyoo Chowanadisai; Ahmed Bettaieb
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

Review 2.  The Roles of MicroRNA-133 in Gynecological Tumors.

Authors:  Yang Zhou; Zhongping Cheng
Journal:  Gynecol Minim Invasive Ther       Date:  2022-05-04

3.  Effect of miR-133b on progression and cisplatin resistance of triple-negative breast cancer through FGFR1-Wnt-β-catenin axis.

Authors:  Yan Lin; Fengkang Lin; Songyot Anuchapreeda; Rujirek Chaiwongsa; Suwit Duangmano; Bing Ran; Sakorn Pornprasert
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

4.  MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2.

Authors:  Zhen Li; Zekang Ye; Jiazheng Ma; Qian Gu; Jianzhen Teng; Xiaoxuan Gong
Journal:  Int J Mol Med       Date:  2021-05-13       Impact factor: 4.101

Review 5.  Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview.

Authors:  Cristina Elena Staicu; Dragoș-Valentin Predescu; Călin Mircea Rusu; Beatrice Mihaela Radu; Dragos Cretoiu; Nicolae Suciu; Sanda Maria Crețoiu; Silviu-Cristian Voinea
Journal:  Cells       Date:  2020-01-09       Impact factor: 6.600

6.  Reversal of glucocorticoid resistance in Acute Lymphoblastic Leukemia cells by miR-145.

Authors:  Sili Long; Danwei Ren; Fangfang Zhong; Yana Niu; Xiang Qin; Dan Mu; Wenjun Liu
Journal:  PeerJ       Date:  2020-06-16       Impact factor: 2.984

7.  YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.

Authors:  Jie Li; Lei Wu; Meili Pei; Yun Zhang
Journal:  J Ovarian Res       Date:  2020-09-18       Impact factor: 4.234

8.  The Role of miR-31-5p in the Development of Intervertebral Disc Degeneration and Its Therapeutic Potential.

Authors:  Yong Zhou; Mingsi Deng; Jiqing Su; Wei Zhang; Dongbiao Liu; Zhengguang Wang
Journal:  Front Cell Dev Biol       Date:  2021-03-18

9.  miR-145 inhibits mitochondrial function of ovarian cancer by targeting ARL5B.

Authors:  Shuo Zhao; Yun Zhang; Meili Pei; Lei Wu; Jie Li
Journal:  J Ovarian Res       Date:  2021-01-08       Impact factor: 4.234

Review 10.  Small Non-Coding-RNA in Gynecological Malignancies.

Authors:  Shailendra Kumar Dhar Dwivedi; Geeta Rao; Anindya Dey; Priyabrata Mukherjee; Jonathan D Wren; Resham Bhattacharya
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.